Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year
Ongoing Phase II Study Could Support Accelerated Approval
Executive Summary
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
You may also be interested in...
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.
J.P. Morgan Day 3: Preparing For The Future, Whatever That Holds
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Teva promises growth is coming; Relay joins Roche in the KRAS race; UCB embraces the digital age; Agios and Ionis prepare for commercial battles.
Merck & Co Takes Up Astex/Taiho SHP2 Program
Merck & Co joins ranks of big pharma firms pursuing the SHP2 area of oncology as it picks up global rights to a portfolio of inhibitors originating from two affiliates of Japan's Otsuka Pharmaceutical.
Need a specific report? 1000+ reports available
Buy Reports